SE9302396D0 - A novel compound form - Google Patents

A novel compound form

Info

Publication number
SE9302396D0
SE9302396D0 SE19939302396A SE9302396A SE9302396D0 SE 9302396 D0 SE9302396 D0 SE 9302396D0 SE 19939302396 A SE19939302396 A SE 19939302396A SE 9302396 A SE9302396 A SE 9302396A SE 9302396 D0 SE9302396 D0 SE 9302396D0
Authority
SE
Sweden
Prior art keywords
novel compound
compound form
crystallinity
manufacture
useful
Prior art date
Application number
SE19939302396A
Other languages
English (en)
Swedish (sv)
Inventor
Aake *Kaellstroem Lars
Annelie *Nygren Monica
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9302396(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE19939302396A priority Critical patent/SE9302396D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of SE9302396D0 publication Critical patent/SE9302396D0/xx
Priority to TW083105710A priority patent/TW504509B/zh
Priority to IL11019094A priority patent/IL110190A/xx
Priority to HR940385A priority patent/HRP940385B1/xx
Priority to SA94150058A priority patent/SA94150058B1/ar
Priority to IS4186A priority patent/IS2075B/is
Priority to ZA944933A priority patent/ZA944933B/xx
Priority to MA23567A priority patent/MA23257A1/fr
Priority to MYPI94001774A priority patent/MY113274A/en
Priority to EG40794A priority patent/EG21437A/xx
Priority to PCT/SE1994/000680 priority patent/WO1995001977A1/en
Priority to PT94921154T priority patent/PT707580E/pt
Priority to AT94921154T priority patent/ATE212628T1/de
Priority to ES94921154T priority patent/ES2100136T3/es
Priority to HU9503873A priority patent/HU226861B1/hu
Priority to DK94921154T priority patent/DK0707580T3/da
Priority to KR1019960700051A priority patent/KR100353783B1/ko
Priority to EP94921154A priority patent/EP0707580B1/de
Priority to NZ268693A priority patent/NZ268693A/en
Priority to CZ199669A priority patent/CZ288933B6/cs
Priority to SK22-96A priority patent/SK281230B6/sk
Priority to BR9406940A priority patent/BR9406940A/pt
Priority to DE0707580T priority patent/DE707580T1/de
Priority to CA002166794A priority patent/CA2166794C/en
Priority to JP50400595A priority patent/JP3635432B2/ja
Priority to DE69429774T priority patent/DE69429774T2/de
Priority to EP01117362A priority patent/EP1164132A3/de
Priority to MX9405217A priority patent/MX9405217A/es
Priority to YU43694A priority patent/YU49193B/sh
Priority to UA96010059A priority patent/UA43343C2/uk
Priority to SG1996004887A priority patent/SG52464A1/en
Priority to US08/313,342 priority patent/US5900424A/en
Priority to AU71981/94A priority patent/AU679766B2/en
Priority to RU96102079A priority patent/RU2139868C1/ru
Priority to PL94312440A priority patent/PL175999B1/pl
Priority to CN94192733A priority patent/CN1064680C/zh
Priority to TNTNSN94079A priority patent/TNSN94079A1/fr
Priority to SI9430414T priority patent/SI0707580T1/xx
Priority to EE9400405A priority patent/EE03127B1/xx
Priority to DZ940071A priority patent/DZ1792A1/fr
Priority to NO960068A priority patent/NO308702B1/no
Priority to FI960101A priority patent/FI114154B/fi
Priority to GR970300015T priority patent/GR970300015T1/el
Priority to HK98109227A priority patent/HK1008329A1/xx
Priority to JP2001293480A priority patent/JP3878826B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Conductive Materials (AREA)
  • Contacts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Powder Metallurgy (AREA)
SE19939302396A 1993-07-09 1993-07-09 A novel compound form SE9302396D0 (sv)

Priority Applications (45)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form
TW083105710A TW504509B (en) 1993-07-09 1994-06-23 A novel form of magnesium omeprazole, its preparation process and pharmaceutical composition comprising the same
IL11019094A IL110190A (en) 1993-07-09 1994-07-01 Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity
HR940385A HRP940385B1 (en) 1993-07-09 1994-07-01 Novel compound form
SA94150058A SA94150058B1 (ar) 1993-07-09 1994-07-04 مركب ملح مغنسيوم الاومبرازول
IS4186A IS2075B (is) 1993-07-09 1994-07-05 Aðferð til að framleiða magnesíumómeprasól
EG40794A EG21437A (en) 1993-07-09 1994-07-07 Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion
MYPI94001774A MY113274A (en) 1993-07-09 1994-07-07 Omeprazole magnesium salt form
ZA944933A ZA944933B (en) 1993-07-09 1994-07-07 A novel compound form
MA23567A MA23257A1 (fr) 1993-07-09 1994-07-07 Nouvelle forme de compose demagnesium d'omeprazole etson utilisation .
TNTNSN94079A TNSN94079A1 (fr) 1993-07-09 1994-07-08 Une nouvelle forme de compose
SI9430414T SI0707580T1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
BR9406940A BR9406940A (pt) 1993-07-09 1994-07-08 Magnésio-omeprazol processo para a preparação de magnésio-omeprazol composição farmacêutica formulação farmacêutica para a administração oral forumulação de tablete uso do magnesio-omeprazol processo para a inibição da secreção de ácido gástrico em mamiferos e no homem e processo para o tratamento das doenças relacionadas com o ácido gastrico em mamiferos e no homem
MX9405217A MX9405217A (es) 1993-07-09 1994-07-08 Proceso para la fabricacion de sal de magnesio de omeprazol, productoobtenido a partir del mismo y composicion farmaceutica que contiene dichoproducto.
AT94921154T ATE212628T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
ES94921154T ES2100136T3 (es) 1993-07-09 1994-07-08 Omeprazol de magnesio.
HU9503873A HU226861B1 (en) 1993-07-09 1994-07-08 Magnesium salt of omeprazole
DK94921154T DK0707580T3 (da) 1993-07-09 1994-07-08 Magnesiumomeprazol
KR1019960700051A KR100353783B1 (ko) 1993-07-09 1994-07-08 마그네슘오메프라졸
EP94921154A EP0707580B1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
NZ268693A NZ268693A (en) 1993-07-09 1994-07-08 Magnesium omeprazole having a degree of crystallinity greater than 70%
CZ199669A CZ288933B6 (cs) 1993-07-09 1994-07-08 Magnezium omeprazol
SK22-96A SK281230B6 (sk) 1993-07-09 1994-07-08 Magnézium omeprazol, spôsob jeho výroby, farmaceutické prípravky s jeho obsahom a jeho použitie
PCT/SE1994/000680 WO1995001977A1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
DE0707580T DE707580T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
CA002166794A CA2166794C (en) 1993-07-09 1994-07-08 Magnesium omeprazole
JP50400595A JP3635432B2 (ja) 1993-07-09 1994-07-08 オメプラゾールマグネシウムの製法
DE69429774T DE69429774T2 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
EP01117362A EP1164132A3 (de) 1993-07-09 1994-07-08 Kristallines Magnesiumomeprazol
PT94921154T PT707580E (pt) 1993-07-09 1994-07-08 Omeprazole magnesio
YU43694A YU49193B (sh) 1993-07-09 1994-07-08 Magnezijum omeprazol i postupak za dobijanje ovog jedinjenja
UA96010059A UA43343C2 (uk) 1993-07-09 1994-07-08 Магнієва сіль омепразолу, спосіб її одержання, фармацевтична композиція, спосіб лікування
SG1996004887A SG52464A1 (en) 1993-07-09 1994-07-08 A novel compound form
US08/313,342 US5900424A (en) 1993-07-09 1994-07-08 Omeprazole magnesium salt form
AU71981/94A AU679766B2 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
RU96102079A RU2139868C1 (ru) 1993-07-09 1994-07-08 Магниевая соль омепразола, способ ее получения, фармацевтическая композиция, способ лечения
PL94312440A PL175999B1 (pl) 1993-07-09 1994-07-08 Omeprazol magnezowy i sposób wytwarzania omeprazolu magnezowego oraz kompozycja farmaceutyczna go zawierająca
CN94192733A CN1064680C (zh) 1993-07-09 1994-07-08 奥美拉唑镁的制备方法
EE9400405A EE03127B1 (et) 1993-07-09 1994-11-17 Kristalne magneesiumomeprasool, selle valmistamise protsess, seda sisaldavad ravimpreparaadid ja nende kasutamine
DZ940071A DZ1792A1 (fr) 1993-07-09 1994-11-27 Une nouvelle forme de composé.
NO960068A NO308702B1 (no) 1993-07-09 1996-01-05 Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav
FI960101A FI114154B (fi) 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi
GR970300015T GR970300015T1 (en) 1993-07-09 1997-05-30 Magnesium omeprazole
HK98109227A HK1008329A1 (en) 1993-07-09 1998-07-17 Magnesium omeprazole
JP2001293480A JP3878826B2 (ja) 1993-07-09 2001-09-26 オメプラゾールマグネシウム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (1)

Publication Number Publication Date
SE9302396D0 true SE9302396D0 (sv) 1993-07-09

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Country Status (42)

Country Link
US (1) US5900424A (de)
EP (2) EP1164132A3 (de)
JP (2) JP3635432B2 (de)
KR (1) KR100353783B1 (de)
CN (1) CN1064680C (de)
AT (1) ATE212628T1 (de)
AU (1) AU679766B2 (de)
BR (1) BR9406940A (de)
CA (1) CA2166794C (de)
CZ (1) CZ288933B6 (de)
DE (2) DE707580T1 (de)
DK (1) DK0707580T3 (de)
DZ (1) DZ1792A1 (de)
EE (1) EE03127B1 (de)
EG (1) EG21437A (de)
ES (1) ES2100136T3 (de)
FI (1) FI114154B (de)
GR (1) GR970300015T1 (de)
HK (1) HK1008329A1 (de)
HR (1) HRP940385B1 (de)
HU (1) HU226861B1 (de)
IL (1) IL110190A (de)
IS (1) IS2075B (de)
MA (1) MA23257A1 (de)
MX (1) MX9405217A (de)
MY (1) MY113274A (de)
NO (1) NO308702B1 (de)
NZ (1) NZ268693A (de)
PL (1) PL175999B1 (de)
PT (1) PT707580E (de)
RU (1) RU2139868C1 (de)
SA (1) SA94150058B1 (de)
SE (1) SE9302396D0 (de)
SG (1) SG52464A1 (de)
SI (1) SI0707580T1 (de)
SK (1) SK281230B6 (de)
TN (1) TNSN94079A1 (de)
TW (1) TW504509B (de)
UA (1) UA43343C2 (de)
WO (1) WO1995001977A1 (de)
YU (1) YU49193B (de)
ZA (1) ZA944933B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
KR100384960B1 (ko) 1994-07-08 2003-08-21 아스트라제네카 악티에볼라그 다단위정제투여형i
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
ES2222754T3 (es) * 1998-11-18 2005-02-01 Astrazeneca Ab Procedimiento quimico mejorado, y formulacion farmaceutica.
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
AU5248601A (en) * 2000-05-15 2001-11-26 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
CA2417311C (en) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
EP1469839A2 (de) * 2002-01-25 2004-10-27 Santarus, Inc. Transmukosale verabreichung von protonenpumpeninhibitoren
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1633736A1 (de) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salz eines benzimidazol-derivats
TWI398273B (zh) * 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005007117A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1801110A1 (de) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Argininsalz des Esomeprazols
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
WO2008012621A2 (en) 2006-07-25 2008-01-31 Vecta, Ltd. Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2068841B1 (de) 2006-10-05 2018-09-26 Santarus, Inc. Neuartige formulierungen von protonenpumpenhemmern und verfahren zu ihrer verwendung
EP2486910A3 (de) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Vorrichtung mit mehreren Kammern und Dispenser
EP1947099A1 (de) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Verfahren zur Entfernung von Lösungsmitteln in Omeprazol-Salzen
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
EP2280969A1 (de) 2008-04-29 2011-02-09 F. Hoffmann-La Roche AG Pyrimidinylpyridonhemmer aus jnk
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2147918A1 (de) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von S-Omeprazol-Magnesium in einer stabilen Form
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
AU2010266026B2 (en) * 2009-06-25 2014-08-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Method for treating a patient in need of aspirin therapy
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2519229A2 (de) 2009-12-29 2012-11-07 Novartis AG Neue pharmazeutische darreichungsform zur behandlung von magensäurebedingten erkrankungen
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (de) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Säurelabile Arzneimittelformulierungen
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
ES2100136T1 (es) 1997-06-16
NO308702B1 (no) 2000-10-16
EG21437A (en) 2001-10-31
EP1164132A3 (de) 2002-01-02
SG52464A1 (en) 1998-09-28
MA23257A1 (fr) 1995-04-01
AU679766B2 (en) 1997-07-10
PL312440A1 (en) 1996-04-29
WO1995001977A1 (en) 1995-01-19
BR9406940A (pt) 1996-09-10
EP1164132A2 (de) 2001-12-19
NO960068D0 (no) 1996-01-05
GR970300015T1 (en) 1997-05-31
UA43343C2 (uk) 2001-12-17
YU49193B (sh) 2004-09-03
MX9405217A (es) 1995-01-31
NZ268693A (en) 1997-05-26
DK0707580T3 (da) 2002-04-15
CN1064680C (zh) 2001-04-18
EP0707580A1 (de) 1996-04-24
CZ288933B6 (cs) 2001-09-12
TNSN94079A1 (fr) 1995-04-25
ATE212628T1 (de) 2002-02-15
EE03127B1 (et) 1998-10-15
HU226861B1 (en) 2009-12-28
PL175999B1 (pl) 1999-03-31
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
JP3635432B2 (ja) 2005-04-06
PT707580E (pt) 2002-06-28
HRP940385A2 (en) 1997-02-28
IL110190A0 (en) 1994-10-21
DE69429774D1 (de) 2002-03-14
CA2166794C (en) 1997-03-04
HK1008329A1 (en) 1999-05-07
FI960101A (fi) 1996-01-09
NO960068L (no) 1996-01-05
ES2100136T3 (es) 2002-09-01
FI114154B (fi) 2004-08-31
IL110190A (en) 2000-07-26
HU9503873D0 (en) 1996-02-28
ZA944933B (en) 1995-02-20
IS2075B (is) 2005-12-15
SI0707580T1 (en) 2002-06-30
AU7198194A (en) 1995-02-06
CN1126993A (zh) 1996-07-17
YU43694A (sh) 1997-07-31
JP2002105072A (ja) 2002-04-10
HRP940385B1 (en) 2003-06-30
MY113274A (en) 2002-01-31
SA94150058B1 (ar) 2006-06-20
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
RU2139868C1 (ru) 1999-10-20
JP3878826B2 (ja) 2007-02-07
CZ6996A3 (en) 1996-05-15
FI960101A0 (fi) 1996-01-09
DE707580T1 (de) 1997-09-04
IS4186A (is) 1995-01-10
HUT75314A (en) 1997-05-28
DZ1792A1 (fr) 2002-02-17
EP0707580B1 (de) 2002-01-30
JPH08512315A (ja) 1996-12-24
TW504509B (en) 2002-10-01
DE69429774T2 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
DK0707580T3 (da) Magnesiumomeprazol
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
RO114325B1 (ro) Derivaţi de sulfonilaminopirimidină şi procedeu de obţinere a acestora
NO179834C (no) Substituerte cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
AU5778894A (en) Process for producing alkoxyiminoacetamide compounds and the production of intermediate compounds used in the process
HUT55033A (en) Process for producing aminooligohydroxy derivatives and pharmaceutical compositions comprising same
HUT46321A (en) Process for producing pyrethrinoid derivatives